Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-24T23:22:19.907Z Has data issue: false hasContentIssue false
  • English
  • Français

Development of a Guideline for the Management of Ventilator-Associated Pneumonia Based on Local Microbiologic Findings and Impact of the Guideline on Antimicrobial Use Practices

Published online by Cambridge University Press:  02 January 2015

Timothy H. Dellit ,
Jeannie D. Chan ,
Shawn J. Skerrett  and
Avery B. Nathens
Timothy H. Dellit*
Affiliation:
Harborview Medical Center, Seattle University of Washington, Seattle
Jeannie D. Chan
Affiliation:
Harborview Medical Center, Seattle University of Washington, Seattle
Shawn J. Skerrett
Affiliation:
Harborview Medical Center, Seattle University of Washington, Seattle
Avery B. Nathens
Affiliation:
University of Toronto, Ontario, Canada
*
Harborview Medical Center, 325 9th Ave, Box 359930 Seattle, WA 98104 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To describe the development of a guideline for the management of ventilator-associated pneumonia (VAP) based on local microbiologic findings and to evaluate the impact of the guideline on antimicrobial use practices.

Design.

Retrospective comparison of antimicrobial use practices before and after implementation of the guideline.

Setting.

Intensive care units at Harborview Medical Center, Seattle, Washington, a university-affiliated urban teaching hospital.

Patients.

A total of 819 patients who received mechanical ventilation and who underwent quantitative bronchoscopy between July 1, 2003, and June 30, 2005, for suspected VAP.

Interventions.

Implementation of an evidence-based VAP guideline that focused on the use of quantitative bronchoscopy for diagnosis, administration of empirical antimicrobial therapy based on local microbiologic findings and resistance patterns, tailoring definitive antimicrobial therapy on the basis of culture results, and appropriate duration of therapy.

Results.

During the baseline period, 168 (46.7%) of 360 patients had quantitative cultures that met the diagnostic criteria for VAP, compared with 216 (47.1%) of 459 patients in the period after the guideline was implemented. The pathogens responsible for VAP remained similar between the 2 periods, except that the prevalence of VAP due to carbapenem-resistant Acinetobacter species increased from 1.8% to 15.3% (P < .001), particularly in late-onset VAP. Compared with the baseline period, there was an improvement in antimicrobial use practices after implementation of the guideline: antimicrobial therapy was more frequently tailored on the basis of quantitative culture results (103 [61.3%] of 168 vs 150 [69.4%] of 216 patients; P = .034), there was an increase in the use of appropriate definitive therapy (135 [80.4%] of 168 vs 193 [89.4%] of 216 patients; P = .001), and there wasadecrease in the mean duration oftherapy (12.0vs 10.7days; P = .0014). The all-cause mortality rate was similar in the periods before and after the guideline was implemented (38 [22.6%] of 168 vs 46 [21.3%] of 216 patients; P = .756).

Conclusions.

Implementation of a guideline for the management of VAP that incorporated the use of quantitative bronchoscopy, the use of empirical therapy based on local microbiologic findings, tailoring of therapy on the basis of culture results, and use of shortened durations of therapy led to significant improvements in antimicrobial use practices without adversely affecting the all-cause mortality rate.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 29 , Issue 6 , June 2008 , pp. 525 - 533
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.American Thoracic Society and Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.Google Scholar
2.Chastre, J, Tagon, J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867–903.Google Scholar
3.Rello, J, Ollendorf, DA, Oster, G, et al. H. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115–2121.Google Scholar
4.Kollef, MH, Sherman, G, Ward, S, Fraser, VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.Google Scholar
5.Pugin, J, Auckenthaler, R, Mili, N, Janssens, JP, Lew, PD, Suter, PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121–1129.Google Scholar
6.Fagon, J-Y, Chastre, J, Wolff, M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. Ann Intern Med 2000;132:621–630.CrossRefGoogle ScholarPubMed
7.Singh, N, Rogers, P, Atwood, CW, Wagener, MM, Yu, VL. Short-course empirical antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 2000;162:505–511.CrossRefGoogle ScholarPubMed
8.Ibrahim, EH, Ward, S, Sherman, G, Schaiff, R, Fraser, VJ, Kollef, MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29:1109–1115.Google Scholar
9.Chastre, J, Wolff, M, Fagon, J-Y. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003;290:2588–2598.Google Scholar
10.Knaus, WA, Wagner, DP, Draper, EA, et al. The APACHE II prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991;100:1619–1636.Google Scholar
11.Kollef, MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(suppl 4):S131–138.Google Scholar
12.Paul, M, Benuri-Silbiger, I, Soares-Weiser, K, Leibovici, L. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and metaanalysis of randomized trials. BMJ 2004;328:668.Google Scholar
13.Bliziotis, IA, Samonis, G, Vardakas, KZ, Chrysanthopoulou, S, Falagas, ME. Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005;41:149–158.Google Scholar